程序性死亡配体1反射诊断检测的批判性评估:当前标准与未来机遇
SP263与22C3在鳞癌和腺癌中一致性达97%至98%,IHC与RNA-ISH及数字与手动评估高度一致,差异多集中在1%临床阈值附近。样本类型和EGFR状态影响PD-L1表达百分比,解读存在挑战。
要点
- SP263与22C3克隆在鳞癌和腺癌中一致性分别为97%和98%。
- IHC与RNA-ISH及数字病理与手动评估均高度一致,差异多在1%阈值附近。
- 样本类型和EGFR状态影响PD-L1表达百分比,判读需注意多种挑战。
核心结论
- 样本类型和EGFR状态决定PD-L1表达百分比的差异。
- PD-L1分析具有挑战性,本文讨论了判读指南。
- RNA-ISH和数字病理的PD-L1评估看似可靠,尤其在腺癌中。
研究设计与样本
- 回顾性分析249例诊断样本,以组织芯片形式。
- 验证的IHC和RNA-ISH方法在组织芯片和全切片上测试,并使用QuPath系统进行数字病理分析。
主要发现
- SP263和22C3克隆在鳞状细胞癌和腺癌中的抗体一致性分别为97%和98%。
- 临床NSCLC病例报告为PD-L1阴性(48%)、1%至49%(23%)和超过50%(29%),差异与组织类型和EGFR状态相关。
- IHC与RNA-ISH在两个亚组中高度一致。
- 数字评估与手动评估高度一致,差异主要围绕1%临床阈值。
临床怎么用
- 判读PD-L1时需注意计算总肿瘤细胞分母及细胞学样本中PD-L1表达细胞聚集的性质。
- 需关注阳性免疫细胞的瘤周表达。
- 在临床阈值附近计算阳性肿瘤百分比需谨慎。
- 需考虑100个恶性细胞规则的相关性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Patient suitability to anti-programmed death ligand 1 (PD-L1) immune checkpoint inhibition is key to the treatment of NSCLC. We present, applied to PD-L1 testing: a comprehensive cross-validation of two immunohistochemistry (IHC) clones; our descriptive experience in diagnostic reflex testing; the concordance of IHC to in situ RNA (RNA-ISH); and application of digital pathology. METHODS: Eight hundred thirteen NSCLC tumor samples collected from 564 diagnostic samples were analyzed prospectively, and 249 diagnostic samples analyzed retrospectively in tissue microarray format. Validated methods for IHC and RNA-ISH were tested in tissue microarrays and full sections and the QuPath system were used for digital pathology analysis. RESULTS: Antibody concordance of clones SP263 and 22C3 validation was 97% to 98% in squamous cell carcinoma and adenocarcinomas, respectively. Clinical NSCLC cases were reported as PD-L1-negative (48%), 1% to 49% (23%), and more than 50% (29%), with differences associated to tissue-type and EGFR status. Comparison of IHC and RNA-ISH was highly concordant in both subgroups. Comparison of digital assessment versus manual assessment was highly concordant. Discrepancies were mostly around the 1% clinical threshold. Challenging IHC interpretation included 1) calculating the total tumor cell denominator and the nature of PD-L1 expressing cell aggregates in cytology samples; 2) peritumoral expression of positive immune cells; 3) calculation of positive tumor percentages around clinical thresholds; and 4) relevance of the 100 malignant cell rule. CONCLUSIONS: Sample type and EGFR status dictate differences in the expected percentage of PD-L1 expression. Analysis of PD-L1 is challenging, and interpretative guidelines are discussed. PD-L1 evaluations by RNA-ISH and digital pathology appear reliable, particularly in adenocarcinomas.
引用
- Humphries MP, McQuaid S, Craig SG, et al. Critical Appraisal of Programmed Death Ligand 1 Reflex Diagnostic Testing: Current Standards and Future Opportunities. J Thorac Oncol. 2018. PMID: 30296485. doi:10.1016/j.jtho.2018.09.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。